The purpose of the study is to determine if BI 764198 is more effective than a placebo at reducing the amount of protein leaked into the urine. During the study, participants will take either the active medication or a placebo in the form of an oral film-coated tablet. The treatment period lasts for 104 weeks, and the process is double-blind, meaning neither the participants nor the researchers know which treatment is being administered during the trial.

The purpose of this study is to evaluate how safe atacicept is and how well it works in reducing the amount of protein in the urine. The medication is given as a subcutaneous injection using a pre-filled syringe. Participants will receive treatment while continuing their regular standard of care medications as prescribed by their doctors.

The study will last for 52 weeks, during which participants will receive regular doses of atacicept. Throughout the study, doctors will monitor various aspects of kidney function, particularly the amount of protein in the urine and how well the kidneys are filtering blood. They will also track the levels of specific disease markers in the blood that are associated with each type of kidney disease.

The purpose of the study is to see how well these treatments can reduce protein levels in the urine, which is a sign of kidney damage. Participants in the study will receive one of the treatments or a placebo and will be monitored over a period of time to assess changes in their condition. The study will also track any side effects or adverse reactions to the treatments.

Participants will be randomly assigned to receive either Frexalimab, SAR442970, Rilzabrutinib, or a placebo. The study will be conducted in a way that neither the participants nor the researchers know who is receiving which treatment, to ensure unbiased results. The trial aims to provide valuable information on the potential benefits and risks of these treatments for people with FSGS or MCD.

Participants in the study will receive either Sparsentan or another medication called Irbesartan, which is commonly used to treat high blood pressure and kidney problems. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving which medication during the trial. This helps ensure that the results are unbiased. The trial will also include an “open-label” phase, where all participants will receive Sparsentan to further assess its long-term effects.

The study will take place over several years, with regular check-ups to monitor kidney function and overall health. Participants will take the medication in tablet form by mouth. The goal is to determine if Sparsentan can effectively reduce the progression of kidney damage in FSGS patients compared to Irbesartan, while also ensuring that it is safe and well-tolerated.

The study involves taking BI 764198 in the form of a capsule, which is taken orally once a day for 12 weeks. Some participants in the study may receive a placebo, a substance with no active therapeutic effect, to compare its effects with those of the actual drug. This is a common practice in clinical studies to ensure accurate results. The scientists will monitor patients closely to assess the effectiveness, safety, and tolerance of the drug. The aim is to find out if BI 764198 can reduce proteinuria in people with FSGS. Participants will undergo regular check-ups and tests to provide researchers with necessary information.

The capsule form makes the drug easy to administer and ensures that participants can continue with their daily activities during the study. This research will provide valuable insight into whether BI 764198 can be a beneficial treatment option for patients with focal segmental glomerulosclerosis.

Participants in the study will receive Sparsentan once daily for a period of 108 weeks. During this time, researchers will monitor the safety of the medication and observe any changes in the levels of protein in the urine, which is a key indicator of kidney health. The study aims to understand how well Sparsentan works in reducing protein levels in the urine and how the body processes the medication over time.

The study will also look at how many participants experience a complete or partial remission of their kidney disease symptoms, such as a significant reduction in protein levels in the urine. Additionally, researchers will track any side effects that occur during the study, including any that might lead to stopping the treatment. This information will help determine the overall safety and potential benefits of Sparsentan for treating these specific kidney diseases in children.

Participants in the study will take the medication R3R01 orally for a period of 12 weeks. During this time, researchers will monitor the safety and tolerability of the medication by checking for any side effects and changes in health indicators such as physical exams, vital signs, and lab tests. The study will also assess how well the medication works in reducing proteinuria in patients with Alport Syndrome and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis.

The study aims to gather information on the quality of life of participants and how it changes from the beginning to the end of the treatment. Additionally, researchers will analyze how the body absorbs and processes the medication. The study will track the number of patients who show a complete or partial response to the treatment in terms of reducing proteinuria at various points during and after the treatment period.

The purpose of the study is to assess how well DMX-200 works in improving kidney function and its safety over time. Participants in the study will be randomly assigned to receive either DMX-200 or a placebo, which looks like the treatment but does not contain the active substance. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the actual treatment or the placebo, ensuring unbiased results. The treatment period will last for several months, during which participants will have regular check-ups to monitor their kidney function and overall health.

In addition to DMX-200, the study involves several ARBs, including Losartan, Candesartan, Telmisartan, Irbesartan, Valsartan, Azilsartan Medoxomil, and Olmesartan Medoxomil. These medications are taken orally and are part of the standard treatment for managing FSGS. The study aims to provide valuable information on the potential benefits of adding DMX-200 to the existing treatment regimen for patients with FSGS.